LJPC La Jolla Pharmaceutical Company

7.38
-0.21  -3%
Previous Close 7.6
Open 7.45
Price To Book -5.13
Market Cap 200,555,959
Shares 27,157,205
Volume 426,216
Short Ratio
Av. Daily Volume 1,395,972
Stock charts supplied by TradingView

NewsSee all news

  1. La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019

    SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  2. La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  3. La Jolla Pharmaceutical Company Announces Management Transition

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  4. La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Progress

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  5. La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development to be discontinued due to lack of efficacy - November 25, 2019.
LJPC-401
Beta thalassemia patients suffering from iron overload
PDUFA date under priority review scheduled for February 28, 2018. Approval announced December 21, 2017.
GiaprezaTM (angiotensin II)
Increase blood pressure in adults with septic or other distributive shock
NDA filed November 4Q 2019.
LJPC-0118
Severe Malaria
Phase 2 data met primary endpoint - June 6, 2019.
LJPC‑401
Hereditary Hemochromatosis

Latest News

  1. La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019

    SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  2. La Jolla to Reassess Continued Development of LJPC-401 Based on Recent Clinical Results

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  3. La Jolla Pharmaceutical Company Announces Management Transition

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  4. La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Progress

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  5. La Jolla Pharmaceutical Company to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve

  6. La Jolla Pharmaceutical Company Receives European Commission Approval for GIAPREZA™ (angiotensin II)

    SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve